N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl-d7]-octadecanamide manufacturers
|
| | N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl-d7]-octadecanamide Basic information |
| | N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl-d7]-octadecanamide Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMF: 0.15 mg/ml | | form | A crystalline solid | | color | Colorless to light yellow | | InChIKey | VODZWWMEJITOND-MUVBWDEFSA-N | | SMILES | OC[C@]([H])(NC(CCCCCCCCCCCCCCCCC)=O)[C@@](O)([H])/C=C/CCCCCCCCCCC(C(C([2H])([2H])[2H])([2H])[2H])([2H])[2H] |
| Storage Class | 11 - Combustible Solids |
| | N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl-d7]-octadecanamide Usage And Synthesis |
| Uses | C18 Ceramide-d7 is used as an internal standard in the spectrometric diagnosis of cardiovascular diseases and complications. | | Biological Activity | C18 ceramide is involved in cell growth inhibition. Determining the levels of the ceramides (Cer) d18:1/16:0, Cer d18:1/18:0, Cer d18:1/24:0, and Cer d18:1/24:1 and ratios in human plasma enables the prognosis of fatal outcome of coronary artery disease. Stable isotope form of C18 ceramide d18:1/18:0 supports a newly described validated liquid chromatography-tandem mass spectrometry methodology for their clinical-scaled measurement. |
| | N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl-d7]-octadecanamide Preparation Products And Raw materials |
|